Delays in obtaining pricing and reimbursement (P&R) have been identified as key hurdles holding back the pharmaceutical industry, according to market analysis. This trend is highlighted through responses to a survey taken from GlobalData’s State of the Biopharmaceutical Industry report, which reveals that industry professionals rate the impact of P&R processes among the top five leading factors currently impacting the sector. GlobalData is the parent company of Pharmaceutical Technology. In the survey, ...

With manufacturing onshoring a continuing point of discussion in the industry, many pharma companies went the opposite way for R&D in 2025, deciding to conduct innovation overseas. According to a survey of pharma executives by consultancy firm Ayming UK, nearly half (47%) of the respondents said they offshored R&D last year. Companies cited collaboration opportunities with partners and proximity to new markets and customers as two of the primary motivating factors for their strategy. Firms also pointed to ...

President Donald Trump called it a way for patients to find the lowest prices on prescription drugs, but TrumpRX is already receiving mixed reviews. TrumpRX is a direct-to-patient purchasing platform for medications. If you’re looking around at the platform or ready to start using it, a prominent voice in American healthcare has a warning about two key aspects that could seriously impact your money. How the Pricing Is Shown Dr. William Soliman, CEO of Accreditation Council for Medical Affairs, said ther ...

Key Takeaways CorMedix's shares fell 27% in 3 months after issuing a cautious 2026 outlook for DefenCath.CRMD expects 2026 revenues of $300-$320M, with DefenCath sales weighted to early 2026.CorMedix acquired Melinta, adding seven therapies to diversify its commercial portfolio beyond DefenCath.Shares of CorMedix (CRMD) have witnessed a sharp decline over the past three months. A key reason for the stocks’ decline during this time has been the company’s bearish 2026 financial outlook. In January, management ...

Core Insights - Cosmos Health Inc. participated in the World Health Expo Dubai 2026, one of the largest healthcare exhibitions globally, held from February 9-12, 2026 [1][3] - The event attracted over 235,000 visitors and 4,300 exhibitors from more than 180 countries, facilitating collaboration among healthcare leaders and innovators [3] Company Highlights - Cosmos Health showcased its proprietary nutraceutical and wellness brands, particularly the Sky Premium Life® line, which is gaining traction through expanded distribution and new product introductions [4][6] - The company also highlighted other brands such as C-Scrub®, an antiseptic wash, and Mediterranation®, a luxury nutritional supplement line featuring organic herbs from the Mediterranean [5][6] - The participation at the Expo allowed Cosmos Health to raise awareness of its manufacturing capabilities and engage with potential partners and distributors [6] Strategic Goals - CEO Greg Siok emphasized the company's commitment to expanding its global footprint and strengthening strategic relationships during the Expo [7] - The company is focused on disciplined growth, brand development, and long-term value creation, with ongoing discussions for potential agreements in regions including Japan, China, and Latin America [7] Company Overview - Cosmos Health Inc., incorporated in 2009, is a diversified global healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands [8] - The company operates under European Good Manufacturing Practices and is involved in manufacturing pharmaceuticals, food supplements, and medical devices within the EU [8] - Cosmos Health is expanding its distribution across Europe, Asia, and North America, with established offices and distribution centers in Greece and the UK [8]

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”), of the important March 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ...

Core Insights - Bristol Myers Squibb's (BMY) revenue performance in 2025 shows a transition with growth from new products offsetting declines in legacy drugs [1][9] - Total revenues were flat year over year, with a 17% increase in sales from the growth portfolio and a 15% decline in legacy products due to generic competition [1][9] Legacy and Growth Portfolio - The legacy portfolio, including drugs like Eliquis, Revlimid, Pomalyst, Sprycel, and Abraxane, is under pressure due to loss of exclusivity for four drugs [2] - The growth portfolio, featuring drugs such as Opdivo, Opdivo Qvantig, Orencia, and others, is crucial for maintaining revenue stability [2] Immuno-Oncology and Key Drug Performance - The immuno-oncology (IO) portfolio, particularly Opdivo, continues to show strong sales momentum due to label expansions and market share growth [3] - Opdivo Qvantig's approval has contributed to growth, with robust initial uptake across approved tumor types in the U.S. [4] - Reblozyl has achieved an annualized sales run rate above $2 billion, while Breyanzi has surpassed $1 billion in annualized sales [5] Future Outlook and Competition - Management anticipates a further decline of 12-16% in legacy sales for 2026, guiding revenues to $46.0-$47.5 billion [7] - BMY faces increasing competition in oncology from companies like Merck, particularly with the success of Keytruda [8][10] Market Performance and Valuation - BMY's shares have gained 12.7% over the past year, compared to the industry's growth of 19.6% [13] - The company is trading at a price/earnings ratio of 9.80x forward earnings, which is lower than the large-cap pharma industry's average of 18.82x [14] Earnings Estimates - The Zacks Consensus Estimate for 2026 EPS has increased to $6.15 from $6.04, while the estimate for 2027 has risen to $5.94 [17]

Core Insights - The conference call is focused on the Duvakitug IBD Ph2b Maintenance Topline Results, indicating a significant development in the company's clinical research efforts [1]. Group 1 - The call is coordinated by Alex, with Chris Stevo serving as the Senior Vice President of Investor Relations, highlighting the company's commitment to transparent communication with stakeholders [2]. - Chris Stevo emphasizes the forward-looking statements made during the call, indicating the company's strategic outlook and future plans [2]. - The company has no obligation to update forward-looking statements, which may suggest a cautious approach to investor communications [2].

Core Viewpoint - Bayer is planning a $10.5 billion settlement initiative to resolve current and future cancer lawsuits related to its Roundup weedkiller, as reported by Bloomberg [1]. Group 1: Settlement Details - The company intends to propose a $7.5 billion class-action settlement for cases filed in Missouri state court, aimed at addressing both existing and potential claims over a 20-year period [1]. - Bayer is also preparing to allocate $3 billion for settlements of ongoing U.S. cases where former Roundup users allege that the herbicide caused their non-Hodgkin's lymphoma [1]. Group 2: Historical Context - Bayer has previously paid approximately $10 billion to settle most Roundup lawsuits that were pending as of 2020, but has not yet secured a settlement for future cases [1]. - New lawsuits have continued to emerge since 2020, with plaintiffs claiming that they developed non-Hodgkin's lymphoma and other cancers due to Roundup usage [1].

Group 1: Clinical Supply Chain Challenges - The clinical development landscape has evolved, yet many supply chains remain outdated, necessitating strategic adaptations for secure patient access, cost control, and high performance [1] - Modern clinical trial supply chains require technology and analytics to manage complexities such as cold storage for biologics and handling cell and gene therapies [1] Group 2: Importance of Partnerships - Strong relationships with Contract Manufacturing Organisations (CMO) and Contract Research Organizations (CRO) are increasingly vital for trial resilience and success in a changing geopolitical environment [2] - Effective communication strategies and the judicious use of technology can enhance oversight and efficiency in R&D [2] Group 3: Conference Insights - The 27th Annual Clinical Trial Supply (CTS) Europe conference will take place in Barcelona on February 24-25, focusing on clinical supply logistics, operations, technology, and innovation [3] - Keynote speaker Arnaud Dourlens from Sanofi will discuss the need for new models in clinical supply chain development due to increasing uncertainties [4] - Following the keynote, discussions will include Sanofi's interactive response technology (IRT) transformation and its impact on drug supply optimization and operational efficiency [5] - UCB's Maite Montes Vallina will address outsourcing challenges and the importance of effective Importer of Record (IOR) and Exporter of Record (EOR) management [6] - A case study on AI application in pharma supply chains will be presented by Sanofi's Landry Giardina, highlighting insights that drive measurable business outcomes [7]